The correlation between tumor MMR status and the outcome in patients treated with immunotherapy has been initially observed in CRCs treated with PD-1 blocker: only 1 of 33 patients with CRCs showed a response to immune-treatment, despite remarkable efficacy of these anticancer agents in other tumor subtypes [40, 41]. The gene discussed is PDCD1; the disease is neoplasm.